|
rs56391007
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusion:</b> Our case-control study suggests that MET T1010I seems to be a risk factor for TNBC in the Caucasian Greek population, in contrast with MET rs40239, where no correlation was found.
|
31213837 |
2019 |
|
rs40239
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Conclusion:</b> Our case-control study suggests that MET T1010I seems to be a risk factor for TNBC in the Caucasian Greek population, in contrast with MET rs40239, where no correlation was found.
|
31213837 |
2019 |
|
rs8176318
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A germline, variant in the BRCA1 3'UTR (rs8176318) was previously shown to predict breast and ovarian cancer risk in women from high-risk families, as well as increased risk of triple negative breast cancer.
|
24915755 |
2014 |
|
rs142030651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A point mutation in the adenoviral E1A binding protein p300 (EP300-G211S) was significantly correlated to this TNBC subgroup.
|
30132219 |
2018 |
|
rs4849887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs2363956
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs13000023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs2077197
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, we identified seven published polymorphism sites in the promoter region and in 3'UTR of PARP1 by sequencing. rs7527192 and rs2077197 genotypes were found to be significantly associated with the cPARP1 expression in TNBC patients (rs7527192 AA+GA versus GG, p=0.014; rs2077197 AA+GA versus GG, p=0.041).
|
26261599 |
2015 |
|
rs9485372
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After grouping breast cancer subtypes, significantly reduced survival was associated with the variant alleles of rs9485372 for luminal A and rs4415084 for triple negative breast cancer.
|
30285756 |
2018 |
|
rs4415084
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After grouping breast cancer subtypes, significantly reduced survival was associated with the variant alleles of rs9485372 for luminal A and rs4415084 for triple negative breast cancer.
|
30285756 |
2018 |
|
rs80350973
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although its low prevalence had not indicated any particular clinical significance in previous studies, our results associated rs80350973 mutation with cell checkpoint malfunction, and was found to be more common in TNBC patients with high Ki-67 indices (P = 0.004).
|
28135048 |
2017 |
|
rs772885662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As a result of a routine BRCA1/BRCA2 mutational screening, we identified a previously unreported BRCA1 sequence alteration [c.5178G>A (V1687I)] in a patient diagnosed with early onset triple negative breast cancer.
|
22527099 |
2012 |
|
rs1064793309
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As a result of a routine BRCA1/BRCA2 mutational screening, we identified a previously unreported BRCA1 sequence alteration [c.5178G>A (V1687I)] in a patient diagnosed with early onset triple negative breast cancer.
|
22527099 |
2012 |
|
rs1651654
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As shown in this analysis, rs1651654 and exm585172 SNPs are found to be determinants of TNBC risk.
|
28918577 |
2018 |
|
rs799917
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Associations between the rs799917 polymorphism and progression risk were investigated after genotyping 370 TNBC patients.
|
28744749 |
2017 |
|
rs473543
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early-stage TNBC patients who received anthracycline-and/or taxane-based regimens as adjuvant chemotherapy.
|
29382381 |
2018 |
|
rs1235679626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Collectively, these findings provide the first functional evidence for the M276I mutation in promoting TNBC progression.
|
30093560 |
2018 |
|
rs769483475
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Collectively, these findings provide the first functional evidence for the M276I mutation in promoting TNBC progression.
|
30093560 |
2018 |
|
rs200928781
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CONCLUSIONS Our findings indicated that CHEK2 Y390C mutation induced the drug resistance of TNBC cells to chemotherapeutic drugs through administrating cell apoptosis and cell cycle arrest via regulating p53 activation and CHEK2-p53 apoptosis pathway.
|
29761796 |
2018 |
|
rs2814778
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Frequency of the Duffy-null allele (rs2814778; an African ancestral variant adopted under selective pressure as protection against malaria) was associated with TNBC-specific risk (P < 0.0001), quantified West African Ancestry (P < 0.0001) and was more common in AA, Ghanaians, and TNBC cases.
|
31356281 |
2019 |
|
rs1412125
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, having one C allele in the rs1412125 domain increased the risk of pathologic grade 3 disease in HER2-enriched and TNBC tumors.
|
29725248 |
2018 |
|
rs3865014
|
|
|
0.010 |
GeneticVariation |
BEFREE |
GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.
|
28734894 |
2017 |
|
rs1485579458
|
|
|
0.010 |
GeneticVariation |
BEFREE |
GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.
|
28734894 |
2017 |
|
rs4986850
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, the D693N SNP was associated with the risk of triple negative breast cancer (odds ratio = 2.31 95% confidence interval 1.08-4.93).
|
23674270 |
2013 |
|
rs1057519847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
|
25789532 |
2015 |